Omnicell (NASDAQ:OMCL) Trading Down 2.4% - What's Next?

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) fell 2.4% during trading on Tuesday . The stock traded as low as $43.19 and last traded at $43.43. 48,856 shares traded hands during trading, a decline of 91% from the average session volume of 542,978 shares. The stock had previously closed at $44.50.

Analyst Ratings Changes

Several brokerages have recently commented on OMCL. JPMorgan Chase & Co. boosted their price target on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Bank of America restated a "neutral" rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Craig Hallum increased their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Barclays raised their target price on Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. Finally, Benchmark reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $52.00.

Omnicell Price Performance

The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -110.77, a P/E/G ratio of 34.96 and a beta of 0.78. The business's 50-day moving average price is $45.58 and its two-hundred day moving average price is $39.65.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company's stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.64% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently bought and sold shares of OMCL. Nisa Investment Advisors LLC increased its position in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock worth $38,000 after buying an additional 1,000 shares during the period. Louisiana State Employees Retirement System lifted its holdings in shares of Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company's stock valued at $625,000 after buying an additional 600 shares during the period. Arkadios Wealth Advisors boosted its stake in Omnicell by 15.1% during the second quarter. Arkadios Wealth Advisors now owns 34,530 shares of the company's stock valued at $935,000 after buying an additional 4,520 shares in the last quarter. Panagora Asset Management Inc. raised its position in Omnicell by 1.6% in the second quarter. Panagora Asset Management Inc. now owns 75,799 shares of the company's stock worth $2,052,000 after acquiring an additional 1,204 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Omnicell by 3.0% during the 2nd quarter. Rhumbline Advisers now owns 147,188 shares of the company's stock valued at $3,984,000 after purchasing an additional 4,281 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.